Genovate Biotechnology Co., Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Genovate Biotechnology Co., Limited with three other
companies in this sector in TAIWAN :
General Biological Corporation
sales of 475.87 million Taiwanese Dollars [US$17.20 million]
UBI Pharma Inc
(477.56 million Taiwanese Dollars [US$17.26 million]
of which 75%
was Contract Medicine Manufacturing), and
TSH Biopharm Corp Limited
(447.86 million Taiwanese Dollars [US$16.19 million]
of which 95%
During the year ended December of 2020, sales at
Genovate Biotechnology Co., Limited were 472.72 million Taiwanese Dollars (US$17.09 million).
a very small
increase of 1.5%
versus 2019, when the company's sales were 465.76 million Taiwanese Dollars .
This was the third consecutive year of growth at Genovate Biotechnology Co., Limited.
The sales level in 2020 was fairly close to the level five years ago: in 2015, Genovate Biotechnology Co., Limited had sales
of 477.60 million Taiwanese Dollars .
Sales of Other saw an increase
that was more than double the company's growth rate: sales were up
1,470.1% in 2020, from
278,000.00 Taiwanese Dollars to 4.37 million Taiwanese Dollars .
Not all segments of Genovate Biotechnology Co., Limited experienced an increase in sales in 2020:
sales of Technical Service fell 39.1% to 2.38 million Taiwanese Dollars .
(However, this segment's sales were only a very small portion of the company's overall sales).
Genovate Biotechnology Co., Limited also experienced decreases in sales in
Agency (down 0.8% to 22.75 million Taiwanese Dollars )